FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3161451006> ?p ?o ?g. }

• W3161451006 endingPage "e002088" @default.
• W3161451006 startingPage "e002088" @default.
• W3161451006 abstract "The majority of patients with recurrent/metastatic squamous cell carcinoma of the head and neck (HNSCC) (R/M) do not benefit from anti-PD-1 therapy. Hypoxia induced immunosuppression may be a barrier to immunotherapy. Therefore, we examined the metabolic effect of anti-PD-1 therapy in a murine MEER HNSCC model as well as intratumoral hypoxia in R/M patients. In order to characterize the tumor microenvironment in PD-1 resistance, a MEER cell line was created from the parental line that are completely resistant to anti-PD-1. These cell lines were then metabolically profiled using seahorse technology and injected into C57/BL6 mice. After tumor growth, mice were pulsed with pimonidazole and immunofluorescent imaging was performed to analyze hypoxia and T cell infiltration. To validate the preclinical results, we analyzed tissues from R/M patients (n=36) treated with anti-PD-1 mAb, via immunofluorescent imaging for number of CD8+ T cells (CD8), Tregs and the percent area (CAIX) and mean intensity (I) of carbonic anhydrase IX in tumor. We analyzed disease control rate (DCR), progression free survival (PFS), and overall survival (OS) using proportional odds and proportional hazards (Cox) regression. We found that anti-PD-1 resistant MEER has significantly higher oxidative metabolism, while there was no difference in glycolytic metabolism. Intratumoral hypoxia was significantly increased and CD8+ T cells decreased in anti-PD-1 resistant tumors compared with parental tumors in the same mouse. In R/M patients, lower tumor hypoxia by CAIX/I was significantly associated with DCR (p=0.007), PFS, and OS, and independently associated with response (p=0.028) and PFS (p=0.04) in a multivariate model including other significant immune factors. During PD-1 resistance, tumor cells developed increased oxidative metabolism leading to increased intratumoral hypoxia and a decrease in CD8+ T cells. Lower tumor hypoxia was independently associated with increased efficacy of anti-PD-1 therapy in patients with R/M HNSCC. To our knowledge this is the first analysis of the effect of hypoxia in this patient population and highlights its importance not only as a predictive biomarker but also as a potential target for therapeutic intervention." @default.
• W3161451006 created "2021-05-24" @default.
• W3161451006 creator A5007717871 @default.
• W3161451006 creator A5009860491 @default.
• W3161451006 creator A5017798446 @default.
• W3161451006 creator A5032809504 @default.
• W3161451006 creator A5035796809 @default.
• W3161451006 creator A5056886978 @default.
• W3161451006 creator A5086074491 @default.
• W3161451006 creator A5088178087 @default.
• W3161451006 date "2021-05-01" @default.
• W3161451006 modified "2023-10-14" @default.
• W3161451006 title "Tumor hypoxia is associated with resistance to PD-1 blockade in squamous cell carcinoma of the head and neck" @default.
• W3161451006 cites W2019607817 @default.
• W3161451006 cites W2131661704 @default.
• W3161451006 cites W2172537925 @default.
• W3161451006 cites W2202401513 @default.
• W3161451006 cites W2401455386 @default.
• W3161451006 cites W2408670508 @default.
• W3161451006 cites W2503407514 @default.
• W3161451006 cites W2529484692 @default.
• W3161451006 cites W2559849011 @default.
• W3161451006 cites W2792997367 @default.
• W3161451006 cites W2799372507 @default.
• W3161451006 cites W2810332541 @default.
• W3161451006 cites W2884883038 @default.
• W3161451006 cites W2885086490 @default.
• W3161451006 cites W2897098821 @default.
• W3161451006 cites W2903493423 @default.
• W3161451006 cites W2913788177 @default.
• W3161451006 cites W2949746977 @default.
• W3161451006 cites W2986633517 @default.
• W3161451006 cites W2988556110 @default.
• W3161451006 cites W2999410311 @default.
• W3161451006 cites W4251207193 @default.
• W3161451006 cites W58194909 @default.
• W3161451006 doi "https://doi.org/10.1136/jitc-2020-002088" @default.
• W3161451006 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8126285" @default.
• W3161451006 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33986123" @default.
• W3161451006 hasPublicationYear "2021" @default.
• W3161451006 type Work @default.
• W3161451006 sameAs 3161451006 @default.
• W3161451006 citedByCount "50" @default.
• W3161451006 countsByYear W31614510062021 @default.
• W3161451006 countsByYear W31614510062022 @default.
• W3161451006 countsByYear W31614510062023 @default.
• W3161451006 crossrefType "journal-article" @default.
• W3161451006 hasAuthorship W3161451006A5007717871 @default.
• W3161451006 hasAuthorship W3161451006A5009860491 @default.
• W3161451006 hasAuthorship W3161451006A5017798446 @default.
• W3161451006 hasAuthorship W3161451006A5032809504 @default.
• W3161451006 hasAuthorship W3161451006A5035796809 @default.
• W3161451006 hasAuthorship W3161451006A5056886978 @default.
• W3161451006 hasAuthorship W3161451006A5086074491 @default.
• W3161451006 hasAuthorship W3161451006A5088178087 @default.
• W3161451006 hasBestOaLocation W31614510061 @default.
• W3161451006 hasConcept C121608353 @default.
• W3161451006 hasConcept C126322002 @default.
• W3161451006 hasConcept C142724271 @default.
• W3161451006 hasConcept C143998085 @default.
• W3161451006 hasConcept C167672396 @default.
• W3161451006 hasConcept C178790620 @default.
• W3161451006 hasConcept C185592680 @default.
• W3161451006 hasConcept C203014093 @default.
• W3161451006 hasConcept C2776090121 @default.
• W3161451006 hasConcept C2776107976 @default.
• W3161451006 hasConcept C2776530083 @default.
• W3161451006 hasConcept C2776833033 @default.
• W3161451006 hasConcept C2777701055 @default.
• W3161451006 hasConcept C2779081379 @default.
• W3161451006 hasConcept C502942594 @default.
• W3161451006 hasConcept C509974204 @default.
• W3161451006 hasConcept C540031477 @default.
• W3161451006 hasConcept C71924100 @default.
• W3161451006 hasConcept C7836513 @default.
• W3161451006 hasConcept C8891405 @default.
• W3161451006 hasConceptScore W3161451006C121608353 @default.
• W3161451006 hasConceptScore W3161451006C126322002 @default.
• W3161451006 hasConceptScore W3161451006C142724271 @default.
• W3161451006 hasConceptScore W3161451006C143998085 @default.
• W3161451006 hasConceptScore W3161451006C167672396 @default.
• W3161451006 hasConceptScore W3161451006C178790620 @default.
• W3161451006 hasConceptScore W3161451006C185592680 @default.
• W3161451006 hasConceptScore W3161451006C203014093 @default.
• W3161451006 hasConceptScore W3161451006C2776090121 @default.
• W3161451006 hasConceptScore W3161451006C2776107976 @default.
• W3161451006 hasConceptScore W3161451006C2776530083 @default.
• W3161451006 hasConceptScore W3161451006C2776833033 @default.
• W3161451006 hasConceptScore W3161451006C2777701055 @default.
• W3161451006 hasConceptScore W3161451006C2779081379 @default.
• W3161451006 hasConceptScore W3161451006C502942594 @default.
• W3161451006 hasConceptScore W3161451006C509974204 @default.
• W3161451006 hasConceptScore W3161451006C540031477 @default.
• W3161451006 hasConceptScore W3161451006C71924100 @default.
• W3161451006 hasConceptScore W3161451006C7836513 @default.
• W3161451006 hasConceptScore W3161451006C8891405 @default.
• W3161451006 hasFunder F4320337351 @default.
• W3161451006 hasIssue "5" @default.

• next